(or prior dosage if less). Monitor patients for signs and symptoms of venetoclax toxicity such as hematologic toxicity, GI toxicity, and tumor lysis syndrome. In a drug interaction study (n = 11), the venetoclax Cmax and AUC values were increased by 106% and 78%, respectively, when a P-gp inhibitor was co-administered in healthy subjects.
Nicardipine: Avoid the concomitant use of venetoclax and nicardipine. Venetoclax is a substrate of CYP3A4 and P-glycoprotein (P-gp) and may be a P-gp inhibitor at therapeutic dose levels in the gut; nicardipine is an inhibitor of CYP3A4 (in vitro) and P-gp and a P-gp substrate (in vitro). Consider alternative agents. If concomitant use of these drugs is required, reduce the venetoclax dosage by at least 50% (maximum dose of 200 mg/day) and consider administering nicardipine at least 6 hours before venetoclax. If nicardipine is discontinued, wait 2 to 3 days and then resume the recommended venetoclax dosage (or prior dosage if less). Monitor patients for signs and symptoms of venetoclax toxicity such as hematologic toxicity, GI toxicity, and tumor lysis syndrome. In a drug interaction study (n = 11), the venetoclax Cmax and AUC values were increased by 106% and 78%, respectively, when a P-gp inhibitor was co-administered in healthy subjects.
Nifedipine: Avoid the concomitant use of venetoclax and nifedipine; venetoclax is a substrate of P-glycoprotein (P-gp) and nifedipine is an inhibitor of P-gp. Consider alternative agents. If concomitant use of these drugs is required, reduce the venetoclax dosage by at least 50% (maximum dose of 200 mg/day). If nifedipine is discontinued, wait 2 to 3 days and then resume the recommended venetoclax dosage (or prior dosage if less). Monitor patients for signs and symptoms of venetoclax toxicity such as hematologic toxicity, GI toxicity, and tumor lysis syndrome. In a drug interaction study (n = 11), the venetoclax Cmax and AUC values were increased by 106% and 78%, respectively, when a P-gp inhibitor was co-administered in healthy subjects.
Nilotinib: Avoid the concomitant use of venetoclax and nilotinib. Venetoclax is a substrate of CYP3A4 and P-glycoprotein (P-gp) and may be a P-gp inhibitor at therapeutic dose levels in the gut; nilotinib is a CYP3A4 and P-gp inhibitor and a P-gp substrate. Consider alternative agents. If concomitant use of these drugs is required, reduce the venetoclax dosage by at least 50% (maximum dose of 200 mg/day) and consider administering nilotinib at least 6 hours before venetoclax. If nilotinib is discontinued, wait 2 to 3 days and then resume the recommended venetoclax dosage (or prior dosage if less). Monitor patients for signs and symptoms of venetoclax toxicity such as hematologic toxicity, GI toxicity, and tumor lysis syndrome. In a drug interaction study (n = 11), the venetoclax Cmax and AUC values were increased by 106% and 78%, respectively, when a P-gp inhibitor was co-administered in healthy subjects.
Ombitasvir; Paritaprevir; Ritonavir: Avoid the concomitant use of venetoclax and lopinavir; ritonavir or ritonavir; venetoclax is a substrate of CYP3A4 and P-glycoprotein (P-gp) and ritonavir is a strong CYP3A4 and P-gp inhibitor. The concomitant use of these agents together is contraindicated during the initial and dose titration phase of venetoclax. If concomitant use of these drugs is required when the patient is on a steady venetoclax dose (after the titration phase), reduce the venetoclax dosage by at least 75% (maximum dose of 100 mg/day). If the strong CYP3A4 inhibitor is |
